Have Palliative Care Teams' Attitudes Toward Venous Thromboembolism Changed? A Survey of Thromboprophylaxis Practice Across British Specialist Palliative Care Units in the Years 2000 and 2005

Journal of Pain and Symptom Management

Volumn 32, Issue 1, 2006, Pages 38-43

  Noble, Simon I R ^a   Finlay, Ilora G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

cancer; hospice; palliative care; Thromboprophylaxis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; AWARENESS; CLINICAL PRACTICE; CONTROLLED STUDY; EXPLORATORY RESEARCH; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PROGNOSIS; TEAMWORK; TELEPHONE; TIME SERIES ANALYSIS; VENOUS THROMBOEMBOLISM;

ATTITUDE OF HEALTH PERSONNEL; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; PALLIATIVE CARE; PRACTICE GUIDELINES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33745636122     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2005.11.013     Document Type: Article

References (28)

1. Trousseau A. Phlegmasia alba dolens. Clinique medicale d'Hotel-Dieu de Paris Vol. 3 (1865), JB Balliere et Fils, Paris pp 654-812
2. Bick R.L. Alterations of haemostasis with malignancy. Semin Thromb Hemost 5 (1978) 1-26
3. Ambrus J.L., Ambrus C.M., and Pickren J.W. Causes of death in cancer patients. J Med 6 (1975) 61-64
4. Johnson M.J., Sproule M.W., and Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 11 (1999) 105-110
5. Wolf R.A. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev 29 Suppl 2 (2003) 7-9
6. Kirwan C.C. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 327 (2003) 597-598
7. Shen V.S., and Pollack E.W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 73 (1980) 841-843
8. Hospice directory 2004. Hospice Information Service, St Christopher's Hospice.
9. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 338S-400S
10. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. Second report, 2004-2005.
11. Barribal K., Christian S., While A., and Bergen A. The telephone survey method: a discussion paper. J Cancer Nurs 24 (1996) 115-121
12. Caprini J.A., Arcelus J.I., and Reyna J.J. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38 Suppl 5 (2001) 12-19
13. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 5 (1999) 285-291
14. Kakkar A.K., Chinswangwatanakul V., Tebbutt S., Lemoine N.R., and Williamson R.C. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 28 1 (1998) 1-6
15. Kakkar A.K., and Williamson R.C. Thromboprophylaxis in the cancer patient. Haemostasis 28 Suppl S3 (1998) 61-65
16. Kakkar V.V., and De Lorenzo F. Prevention of venous thromboembolism in general surgery. Baillieres Clin Haematol 11 3 (1998) 605-619
17. Gathof B.S., Picker S.M., and Rojo J. Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 9 3 (2004) 95-103
18. Hospice directory 2000. Hospice Information Service, St Christopher's Hospice.
19. Turpie A.G. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 86 12B (2000) 48M-52M
20. Lee A.Y., Levine M., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (2003) 146-153
21. Weber C. Prophylaxis of venous thromboembolism (VTE) with low molecular weight heparin in cancer patients hospitalized for palliative care (PC). Abstracts of the 8th Congress of the European Association of Palliative Care, 2003, Abstract 25.
22. Noble S.I.R. Is low molecular weight heparin an acceptable intervention in palliative care patients? A phenomenological study. [abstract]. Palliat Med 18 2 (2004) 150
23. Noble S.I.R. Anticoagulation in advanced malignancy: pitfalls, dangers and future developments. [abstract]. Palliat Med 18 2 (2004) 161
24. Noble S.I.R. Haematological aspects of palliative medicine. In: Watson M., Lucas C., Hoy A., and Back I. (Eds). Oxford handbook of palliative care (2005), Oxford University Press, Oxford 408-417
25. Hunt B.J., and Noble S.I.R. Thrombotic and bleeding complications in haematological malignancies. In: Both S., and Bruera E. (Eds). Palliative care consultations in haemato-oncology (2003), Oxford University Press, Oxford 191-199
26. Course material. Advanced course in pain and symptom management, Sir Michael Sobel House, 2004.
27. Newsletter, April 2005. Available from Palliativedrugs.com. Accessed May 23, 2005.
28. Noble S.I.R., and Finlay I.G. Is long-term low molecular weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19 (2005) 197-201